Trial
NCT03782064
Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Beth Israel Deaconess Medical Center
Collaborators
Bristol-Myers Squibb; Dana-Farber Cancer Institute
Condition
Multiple Myeloma
Intervention
Nivolumab
Why stopped
Funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-06-22